Dieter Gericke (born 1965) joined Homburger in 2000 and became partner in 2004. He heads the corporate M&A practice team as well as the Homburger China group. He studied law at the University of Zürich , where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.
Dieter Gericke's practice focuses on M&A (including public takeovers and defense), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.
Recent assignments include the takeover of Syngenta by ChemChina, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the acquisition of Activ International by Givaudan, the sale of Infront Sports & Media to Dalian Wanda, the acquisition of Ulysse Nardin by Kering, the IPO of Zur Rose Group and the 400 million financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.
In his areas of practice Dieter Gericke authored various publications and legal opinions, including mergers and acquisitions, securities laws, directors' and officers' duties and liability and say-on-pay regulations. He is a member of the IBA corporate | M&A and securities law committees.
Dieter Gericke is a member of the boards of directors of Syngenta AG, a leading agriculture company, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.